Reach Us +1-504-608-239
Nathan Bahary | OMICS International
ISSN: 2577-0535

Journal of Cancer Clinical Trials
Open Access

Like us on:

Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Nathan Bahary


FG-3019, A Human Monoclonal Antibody to Connective Tissue Growth Factor, Combined with Chemotherapy in Patients with Locally Advanced or Metastatic Pancreatic Ductal Adenocarcinoma

Purpose: Connective tissue growth factor (CTGF) is overexpressed in pancreatic ductal adenocarcinoma (PDAC) and facilitates local desmoplasia, tumor progression and metastasis in animal models. This study evaluated safety and initial efficacy of the anti-CTGF antibody FG-3019 in combination with gemcitabine and erlotinib in patients with previously... Read More»

Vincent J Picozzi, J. Marc Pipas, Albert C Koong, Amato J Giaccia, Nathan Bahary, Smitha S Krishnamurthi, Charles D Lopez, Peter O’Dwyer, Katharina Modelska, Mairead Carney, James Chou, Ming Zhong, Stefan Hemmerich, Dongxia Li, Ewa Carrier, Seth Porter, Thomas B Neff and Frank H Valone

Research Article: J Cancer Clin Trials 2017, 2:123

Abstract Peer-reviewed Full Article Peer-reviewed Article PDF Mobile Full Article

Relevant Topics